Tilos Therapeutics, a biotech firm developing anti-LAP antibodies for the treatment of cancer, fibrosis and autoimmune diseases, today announced the appointment of Jessie English as chief scientific officer. 27 June 2018
Aiming to reduce the cost of bulk drugs by 20%-25% and to help small and medium pharmaceutical enterprises (SMEs) upgrade their technology, the Indian government is looking to pump in several millions to support and shore up the drug industry, reports The Pharma Letter’s India correspondent. 27 June 2018
Russia’s President Vladimir Putin has ordered the national government to ease the process of certification of foreign drugs in Russia this year, according to recent statements of the Russian Presidential Administration, reports The Pharma Letter’s local correspondent. 26 June 2018
US health care giant Johnson & Johnson plans a significant expansion of a global portfolio of its drugs during the next several years, according to chief scientific officer of the company Paul Stoffells speaking at an exclusive meeting with Russian media. 26 June 2018
Conference attendees gathered in the cavernous RAI Amsterdam convention center last week to hear the latest data from a therapy area valued at around $44 billion last year, and expected to reach over $50 billion by 2022. 22 June 2018
Roche today announced that Sophie Kornowski-Bonnet, head of Roche Partnering and member of the enlarged corporate executive committee (CEC) since 2012, has accepted a new opportunity and will be leaving the company effective July 31, 2018. 22 June 2018
An Expert View from Lynn Lewis, chief commercial officer of contract research organization Envigo, on why she believes that successful collaboration needs to embrace both proactivity and beginning-with-the-end-in-mind. 21 June 2018
Jesus Gomez-Navarro, vice president, head of oncology clinical research and development at Takeda Oncology, talks of three elements to the unit’s R&D strategy and three highlights in its pipeline when talking to The Pharma Letter about the most exciting abstracts being presented on the company’s cancer candidates at two major conferences this month. 20 June 2018
French pharma major Sanofi has appointed Jean-Baptiste Chasseloup de Chatillon as executive vice president, chief financial officer (CFO) and member of the executive committee, effective October 1, 2018. 19 June 2018
A Russian pharmaceutical company for the first time has received a license for the production an analogue of a drug in Russia, the rights for which are owned by a global drugmaker, reports The Pharma Letter local correspondent. 15 June 2018
Ipsen has been in oncology for a long time — since the 1980s in fact. It's one of the field's top 20 companies. But in a market that’s turbulent, spilling over with established titans and up-and-comers alike, how does the French firm manage to maintain its edge? 15 June 2018
The production of drugs in Russia this year may show record low figures, due to the current glut in the Russian pharmaceutical market and the reduction of morbidity rate in certain disease areas, according to recently published data of the Russian Ministry of Health, reports The Pharma Letter’s local correspondent. 14 June 2018
In an oral presentation to be given at the annual meeting of the European League Against Rheumatism (EULAR), US-based Celgene will present a post hoc analysis of data from the PALACE trial program that suggest new, previously uncaptured benefits of Otezla (apremilast) against psoriatic arthritis. 14 June 2018
Lev Gerlovin (pictured left) and Walter Colasante are vice presidents at the life sciences division of Charles River Associates. Writing for The Pharma Letter, they seek to address the challenges posed to the existing biopharma business model by revolutionary, but prohibitively expensive, cell and gene therapies. 13 June 2018
Indian pharma majors selling copycat drugs in the USA are facing the heat given the steep competition and pricing pressure, and President Donald Trump's new policy on lowering drug prices, reports The Pharma Letter’s India correspondent. 12 June 2018
China’s Zai Lab, a Shanghai-based innovative biopharmaceutical company, has appointed that William Liang as chief commercial officer, reporting to Dr Samantha Du, Zai Lab’s chief executive. 11 June 2018
Experts from the International Society for Cell and Gene Therapy (ISCT) told The Pharma Letter last month that the last 12 months had been the most important yet for advances in their field. 10 June 2018
French independent pharma company Servier today announced the appointments of Christian Schubert and Rekha Paleyanda as directors of Servier BioInnovation along with the opening of the Servier BioInnovation office in Cambridge, Massachusetts. 7 June 2018
Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
The shortage of drugs in Russia is deepening, and is currently being observed in almost 70 regions throughout the country and forcing the local state to consider ways to resume stable supplies to local market, reports The Pharma Letter’s local correspondent. 13 August 2024
US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 7 August 2024
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
Domestic drugs and foreign drugs, the production of which is localized in Russia, will be given a priority when included in the list of vital and essential drugs (VED) and expensive drugs, according to a recent resolution signed by the Russian government, The Pharma Letter’s local correspondent reports. 1 August 2024